Troglitazione affects survival of human osteosarcoma cells

Enrico Lucarelli, Luca Sangiorgi, Veronica Maini, Giovanna Lattanzi, Sandra Marmiroli, Matteo Reggiani, Marina Mordenti, Giuliana Alessandra Gobbi, Francesca Scrimieri, Annarosa Zambon Bertoja, Piero Picci

    Research output: Contribution to journalArticlepeer-review

    32 Scopus citations

    Abstract

    Activation of PPARγ, a transcription factor member of the family of peroxisome proliferator-activated receptors, induces apoptosis in several normal and tumor cell lines. In our study, we investigated whether treatment with troglitazone (TRO), a known PPARγ agonist, induced apoptosis in the human osteosarcoma (OS) cell lines G292, MG63, SAOS and U2OS that express PPARγ. In our experiments, TRO never induced apoptosis of OS cells; on the contrary, TRO increased cell number, based on MTT proliferation assay. Remarkably, the TRO-induced cell number increase depended on a decrease of apoptosis that naturally occurred in the culture and was not due to an increased cell proliferation rate. TRO also prevented staurosporin-induced apoptosis. The TRO-mediated survival effect correlated with the activation of Akt, a well-known mediator of survival stimuli. Our work describes a new function for TRO and indicates that the Akt survival pathway may be a mediator of TRO-induced increase of survival.

    Original languageEnglish (US)
    Pages (from-to)344-351
    Number of pages8
    JournalInternational Journal of Cancer
    Volume98
    Issue number3
    DOIs
    StatePublished - Mar 20 2002

    Keywords

    • Apoptosis
    • Nuclear receptors
    • Osteosarcoma
    • Survival

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Troglitazione affects survival of human osteosarcoma cells'. Together they form a unique fingerprint.

    Cite this